Resources

“Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2″

[read more]

15
Mar

“Oleandrin, a cardiac glycoside, induces immunogenic cell death via the PERK/elF2α/ATF4/CHOP pathway in breast cancer”

[read more]

06
Mar

“Antiviral Effects of Oleandrin”

[read more]

“The Botanical Drug PBI-05204, a Supercritical CO₂ extract of Nerium oleander, Inhibits Growth of Human Glioblastoma, Reduces Akt/mTOR Activities, and Modulates GSC Cell-Renewal Properties”

[read more]

PBI sponsored research at the University of Texas at San Antonio has demonstrated that PBI-05204 leads to a marked reduction in neuroinflammtion in brain microglial cells in vitro.

[read more]

08
Feb

A recent 2020 publication has shown that oleandrin effectively and selectively targets human breast cancer cells without affecting normal breast epithelial cells. The selectivity is based in part on the relative content of Na,K-ATPase alpha-3 subunit as previously shown by Phoenix Biotechnology scientists.

READ PUBLICATION[read more]

07
Feb

Camargo Pharmaceutical Services, LLC offers support to Phoenix Biotechnology Inc. in the development of PBI-05204, for the treatment of various tropical diseases eligible to receive priority review vouchers.

[read more]

Phoenix Biotechnology has entered the Patents For Humanity awards competition sponsored by the United States Patent & Trademark Office.

[read more]

New research findings presented in November at the Italian Cancer Society’s 61st annual meeting in Naples, Italy

[read more]

“The Botanical Glycoside Oleandrin Inhibits Human T-cell Leukemia Virus Type-1 Infectivity and Env-Dependent Virological Synapse Formation”.

[read more]

“Oleandrin sensitizes human osteosarcoma cells to cisplatin by preventing degradation of the copper transporter 1”

Yong L, Ma Y, et al. Phtyother. Res. 2019 May. This article shows that oleandrin[read more]

“Oleandrin and its derivative Odoroside A, both cardiac glycosides, exhibit anticancer effects by inhibiting invasion via suppressing the STAT-3 signaling pathway”.

Intnl. J. Mol. Sci. 2018, 19(11); 3350. Ko YS, Rugira T, Jin H, Park SW[read more]

HTLV-1.

HTLV stands for Human T-cell Leukemia Virus. It is a retrovirus that infects a type[read more]

06
Mar

Glioblastoma research

[read more]

“Neuroprotective and tumoricidal activities of cardiac glycosides. Could oleandrin be a new weapon against stroke and glioblastoma?”

[read more]

A research project with Dr. Xiao-Nan Li, Baylor College of Medicine and Brain Tumor Program/Texas Children’s Hospital is showing encouraging results of PBI’s oleander extract both when used alone as well as in combination with radiotherapy against glioblastoma (brain cancer). Studies are ongoing.

[read more]

The U.S. Army Medical Research Institute together with Dr. R. Newman (PBI Chief Science Officer) presented research with PBI’s oleander extract at the 9th International Symposium on Filoviruses held in Marburg, Germany.

The data presented showed highly significant inhibition of Ebola virus. Research is ongoing with respect[read more]

The U.S. Army Medical Research Institute of Infectious Disease (Ft. Detrick, MD) has completed promising preclinical research with PBI’s lead oleander extract and found it to be highly effective against Ebola and Marburg viruses.

[read more]

An independent research group from Sapienza University in Italy has reported that oleandrin (key component in PBI-05204) significantly increased mouse survival and reduced brain tumor growth both directly on tumor cells and indirectly by promoting an antitumor brain microenvironment with a key protective role played by brain derived neurotrophic factor (BDNF).

[read more]

Because the active principle ingredient in PBI-05204 readily crosses the blood brain barrier (BBB) it has the potential to benefit malignant disease that resides in the brain.

PBI has initiated research on pediatric glioblastoma multiforma (GBM) together with Dr. Xiao-Nan Li (Brain[read more]

PBI is extremely pleased to announce an expansion of their Scientific Advisory Board to include world class experts in antiviral, neurodegenerative disease and cancer related research fields.

Please see the SAB tab on this web page to view current SAB members, institutional[read more]

05
Jan

PBI is in the process of concluding its Phase II trial of PBI-05204 against advanced, drug refractory pancreatic cancer.

This disease is often diagnosed only after it has metastasized throughout the body making any[read more]

Pharmacokinetics and Comparative Effects of Frondosides in Pancreatic Cancer

by: Jasem Al Shemaili, Khatija Parekh, Robert Newman, Björn Hellman, Carl Woodward, Abdu Adem, Peter[read more]

Dual activities of the anti-cancer drug candidate PBI-05204 provide neuroprotection in brain slice models for neurodegenerative diseases and stroke

[read more]

PBI is pleased to announce an excellent rate of accrual of advanced pancreatic cancer patients to their Phase II clinical study.

To date, 37 patients of the target goal of 50 have been entered on the[read more]

Research with colleagues at Duke University continues to reveal important brain mediated benefits in response to PBI-05204.

Not only have our two published studies shown an increase in brain derived neurotrophic factor[read more]

NIH has expressed an interest in exploring the potential of PBI-05204 to alleviate the extreme fatigue often associated in cancer patients undergoing radiation therapy.

[read more]

We are pleased to announce that by the end of this month there will be 5 clinical sites open across the USA that are approved to enroll patients to our Phase II trial for treatment of advanced pancreatic cancer.

[read more]

In late December, 2014 the FDA approved of our plans to take PBI-05204 forward into clinical Phase II trials.

[read more]

A manuscript describing the therapeutic effects of PBI-05204 against human pancreatic cancer implanted orthotopically (within the pancreas) in immunocompromised mice has been accepted for publication in Investigational New Drugs

[read more]

A manuscript describing the results of the Phase I trial of PBI-05204 conducted at the Univ. Texas M. D. Anderson Cancer Center has been published in Investigational New Drugs.

[read more]

Additional testing of PBI-05204 against patient derived tumors is being conducted at Rational Therapeutics (San Diego, CA).

[read more]

BDNF Mediates Neuroprotection against Oxygen-Glucose Deprivation by the Cardiac Glycoside Oleandrin.

[read more]

Presentation Abstract: PBI-05204, a supercritical CO2 extract of Nerium oleander, inhibits the growth of human pancreatic cancer in a Panc-1 orthotopic model by down-regulation of PI3k/mTOR pathways.

Dr. Robert A. Newman, our Chief Science Officer will be presenting at the Beaujon Conference[read more]

Presentation Abstract: PBI-05204, a supercritical CO2 extract of Nerium oleander, inhibits the growth of human pancreatic cancer in a Panc-1 orthotopic model by down-regulation of PI3k/mTOR pathways.

Yong Pan, Sun-Jin Kim, Patrea Rhea, Carrie Cartwright, Ho Jeong Lee, Crandell Addington, Mihai Gagea,[read more]

Nerium oleander derived cardiac glycoside oleandrin is a novel inhibitor of HIV infectivity.

Singh S, Shenoy S, Nehete PN, Yang P, Nehete B, Fontenot D, Yang G, Newman[read more]

Digoxin and ouabain induce the efflux of cholesterol via liver X receptor signalling and the synthesis of ATP in cardiomyocytes.

Campia I, Sala V, Kopecka J, Leo C, Mitro N, Costamagna C, Caruso D, Pescarmona[read more]

Cellular location and expression of Na+, K+-ATPase α subunits affect the anti-proliferative activity of oleandrin.

Yang, P., Cartwright, C., Efuet, E., Hamilton, S. R., Wistuba, I. I., Menter, D., Addington,[read more]

Research Article: Cardiac glycosides exert anticancer effects by inducing immunogenic cell death.

Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, Yamazaki T, Sukkurwala[read more]

Phoenix Biotechnology executes a seventh amendment to its Sponsored Research Agreement with M. D. Anderson Cancer Center.

[read more]

Phoenix Biotechnology enters into a research agreement with Rational Therapeutics, Inc. to conduct examination of antitumor effects of PBI-05204 on human tumor biopsy samples (an ‘in vitro’ Phase II study).

Publication: In vitro and in vivo neuroprotective activity of the cardiac glycoside oleandrin from Nerium oleander in brain slice-based stroke models.

Dunn DE, He DN, Yang P, Johansen M, Newman RA, Lo DC. J Neurochem. 2011[read more]

Phoenix executes a Sponsored Research Agreement with Duke University for in vivo research in animal models to study prevention of ischemic stroke using PBI-05204.

[read more]

ASCO annual meeting poster presentation along with an oral format with discussion of clinical trial results of PBI-05204.

Phoenix Biotechnology executes a sixth amendment to its Sponsored Research Agreement with M. D. Anderson Cancer Center.

[read more]

Phase I Clinical Trial of PBI-05204 successfully completed at M. D. Anderson Cancer Center.

[read more]

Phoenix Biotechnology executes a fifth amendment to its Sponsored Research Agreement with M. D. Anderson Cancer Center.

[read more]

Phoenix raises >$3,000,000 from angel investors.

[read more]

Publication: Human tumor cell sensitivity to oleandrin is dependent on relative expression of Na+, K+ -ATPase subunits.

Lin Y, Ho DH, Newman RA. J Exp Ther Oncol. 2010;8(4):271-86. PMID: 21222360[read more]

Phoenix Biotechnology executes a fourth amendment to its Sponsored Research Agreement with M. D. Anderson Cancer Center.

[read more]

Society of Integrative Oncology (SIO) International Conference- comprehensive poster presentation with discussion.

[read more]

Phoenix Biotechnology executes a third amendment to its Sponsored Research Agreement with M. D. Anderson Cancer Center.

Publication: Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na,K-ATPase alpha subunits as drug[read more]

Update on Phase I trial of PBI-05204: ASCO annual meeting poster presentation with discussion.

Phoenix Biotechnology executes a Sponsored Research Agreement with Duke University for in vitro research in neurological disorders using PBI-05204 and certain discrete fractions of the whole extract.

[read more]

Phoenix Biotechnology executes a second amendment to its Sponsored Research Agreement with M. D. Anderson Cancer Center.

Publication: Determinants of human and mouse melanoma cell sensitivities to oleandrin. Lin Y, Dubinsky WP,[read more]

Phoenix raises >$3,000,000 from angel investors.

[read more]

Publication: Cardiac glycosides as novel cancer therapeutic agents. Newman RA, Yang P, Pawlus AD, Block KI. Mol Interv.

PMID: 18332483[read more]

Publication: Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside. Newman RA, Kondo Y, Yokoyama T, Dixon S, Cartwright C, Chan D, Johansen M, Yang P. Integr. Cancer Ther.

PMID: 18048883[read more]

Phoenix executes an amendment to its Sponsored Research Agreement with M. D. Anderson Cancer Center

[read more]

USFDA approves Phoenix IND 73,624 application to conduct a Phase I Trial with PBI-05204, a patented supercritical extract of Nerium oleander, in patients with advanced cancer.

[read more]

Phoenix enters into contract with Quintiles, Inc. to act as Clinical Research Organization for “An Open Label Phase I Trial of PBI-05204 in Advanced Cancer Patients” to be conducted at M. D. Anderson Cancer Center.

[read more]

Phoenix Biotechnology, Inc. executes a share exchange agreement with Nerium Biotechnology, Inc. by which Nerium Biotechnology acquires all the Latin American operations of Phoenix.

[read more]

Publication: Oleandrin-mediated oxidative stress in human melanoma cells. Newman RA, Yang P, Hittelman WN, Lu T, Ho DH, Ni D, Chan D, Vijjeswarapu M, Cartwright C, Dixon S, Felix E, Addington C. J Exp Ther Oncol. 2006;5(3):167-81.

PMID: 16528968[read more]